Anxin Wang
Ticagrelor Aspirin vs Clopidogrel Aspirin in CYP2C19 Loss-of-Function Carriers with Minor Stroke or TIA Stratified by Risk Profile
Wang, Anxin; Meng, Xia; Tian, Xue; Zuo, Yingting; Bath, Philip M.; Li, Hao; Xie, Xuewei; Jing, Jing; Lin, Jinxi; Wang, Yilong; Zhao, Xingquan; Liu, Liping; Li, Zixiao; Jiang, Yong; Xu, Jie; Wang, Feng; Chen, Weifeng; Cao, Minghua; Li, Jianhua; Wang, Yongjun
Authors
Xia Meng
Xue Tian
Yingting Zuo
PHILIP BATH philip.bath@nottingham.ac.uk
Stroke Association Professor of Stroke Medicine
Hao Li
Xuewei Xie
Jing Jing
Jinxi Lin
Yilong Wang
Xingquan Zhao
Liping Liu
Zixiao Li
Yong Jiang
Jie Xu
Feng Wang
Weifeng Chen
Minghua Cao
Jianhua Li
Yongjun Wang
Abstract
Background and ObjectiveGenotype data of the Clopidogrel with Aspirin in Acute Minor Stroke or Transient Ischemic Attack (CHANCE) trial showed that efficacy of clopidogrel aspirin depended on CYP2C19 genotype and risk profile. A stratification of patients who carried CYP2C19 loss-of-function (LOF) alleles according to the risk of recurrent stroke may be important for selecting optimal antiplatelet therapy. We aimed to compare the efficacy and safety of ticagrelor aspirin with clopidogrel aspirin in CYP2C19 LOF carriers with minor stroke or transient ischemic attack (TIA) stratified by risk profile.MethodsData were obtained from Ticagrelor or Clopidogrel with Aspirin in High-Risk Patients with Acute Nondisabling Cerebrovascular Events II (CHANCE-2) trial. Low-risk and high-risk profiles were defined by Essen Stroke Risk Score (ESRS) (<3 [low risk] and ≥3 [high risk], respectively).ResultsA total of 6,412 CYP2C19 LOF carriers were enrolled; ticagrelor aspirin was associated with a reduced risk of primary outcome (new stroke within 90-day follow-up) in patients at low risk (hazard ratio [HR], 0.65; 95% CI, 0.48-0.82), but not in those at high risk (HR, 0.97; 95% CI, 0.73-1.29), compared with clopidogrel aspirin (p = 0.02 for interaction). Secondary outcomes generally went in the same direction as the primary outcome. The primary safety outcome of severe or moderate bleeding did not differ based on risk profile (p = 0.24 for interaction), although the incidence of total bleeding was greater with ticagrelor aspirin than with clopidogrel aspirin among patients at low risk (p < 0.01 for interaction). Analysis in the per-protocol population yielded similar results.DiscussionThis post hoc analysis of CHANCE-2 trial showed that CYP2C19 LOF carriers with minor stroke or TIA at low risk of recurrent stroke received a greater benefit from ticagrelor aspirin than from clopidogrel aspirin.Classification of EvidenceThis study provides Class II evidence that CYP2C19 LOF carriers with minor stroke or TIA at low risk, but not at high risk, of recurrent stroke (by the ESRS) received a greater benefit from ticagrelor aspirin than from clopidogrel aspirin.Trial Registration InformationURL: www.clinicaltrials.gov.
Citation
Wang, A., Meng, X., Tian, X., Zuo, Y., Bath, P. M., Li, H., …Wang, Y. (2023). Ticagrelor Aspirin vs Clopidogrel Aspirin in CYP2C19 Loss-of-Function Carriers with Minor Stroke or TIA Stratified by Risk Profile. Neurology, 100(5), e497-e504. https://doi.org/10.1212/WNL.0000000000201454
Journal Article Type | Article |
---|---|
Acceptance Date | Dec 3, 2022 |
Online Publication Date | Dec 19, 2022 |
Publication Date | Jan 31, 2023 |
Deposit Date | Dec 6, 2022 |
Publicly Available Date | Dec 20, 2023 |
Journal | Neurology |
Print ISSN | 0028-3878 |
Electronic ISSN | 1526-632X |
Publisher | American Academy of Neurology |
Peer Reviewed | Peer Reviewed |
Volume | 100 |
Issue | 5 |
Pages | e497-e504 |
DOI | https://doi.org/10.1212/WNL.0000000000201454 |
Public URL | https://nottingham-repository.worktribe.com/output/14592441 |
Publisher URL | https://n.neurology.org/content/early/2022/12/19/WNL.0000000000201454 |
Files
Ticagrelor-Aspirin versus Clopidogrel-Aspirin in CYP2C19
(261 Kb)
PDF
Ticagrelor-Aspirin versus Clopidogrel-Aspirin in CYP2C19
(397 Kb)
PDF
You might also like
Dysphagia after stroke: research advances in treatment interventions
(2024)
Journal Article
Downloadable Citations
About Repository@Nottingham
Administrator e-mail: discovery-access-systems@nottingham.ac.uk
This application uses the following open-source libraries:
SheetJS Community Edition
Apache License Version 2.0 (http://www.apache.org/licenses/)
PDF.js
Apache License Version 2.0 (http://www.apache.org/licenses/)
Font Awesome
SIL OFL 1.1 (http://scripts.sil.org/OFL)
MIT License (http://opensource.org/licenses/mit-license.html)
CC BY 3.0 ( http://creativecommons.org/licenses/by/3.0/)
Powered by Worktribe © 2024
Advanced Search